References
1. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53(3):373-388.
2. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy.2014;69(5):602-616.
3. Sala-Cunill A, Guilarte M. The role of mast cells mediators in angioedema without wheals. Curr Treat Options Allergy.2015;2(4):294-306.
4. Giavina-Bianchi P, Aun MV, Motta AA, Kalil J, Castells M. Classification of angioedema by endotypes. Clin Exp Allergy.2015;45(6):1142-1143.
5. Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol.2015;114(5):418-419.
6. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy Eur J Allergy Clin Immunol.2018;73(7):1393-1414.
7. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1.Allergy Eur J Allergy Clin Immunol. 2011;66(3):317-330.
8. Sabaté-Brescó M, Rodriguez-Garijo N, Azofra J, et al. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema. J Allergy Clin Immunol Pract.2021;9(6):2284-2292.
9. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy Eur J Allergy Clin Immunol.2017;72(12):2005-2016.
10. Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire.Allergy Eur J Allergy Clin Immunol. 2012;67(10):1289-1298.
11. Nordenfelt P, Nilsson M, Lindfors A, Wahlgren CF, Björkander J. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. Allergy Asthma Proc.2017;38(6):447-455.
12. Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
13. Caballero T, Prior N. Burden of illness and quality-of-life measures in angioedema conditions. Immunol Allergy Clin N Am.2017;37(3):597-616.
14. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting edge: biomarkers for chronic spontaneous urticaria. J Immunol Res.2018;2018:1-12.
15. Kolkhir P, André F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy.2016;47(1):19-36.
16. Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P. Biomarkers in chronic spontaneous urticaria: current targets and clinical implications. J Asthma Allergy. 2019;12:285-295.
17. Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score. Allergy Eur J Allergy Clin Immunol. 2013;68(9):1185-1192.
18. Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093-1101.
19. Sussman G, Abuzakouk M, Bérard F, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy Eur J Allergy Clin Immunol.2018;73(8):1724-1734.
20. Balañá M, Valero A, Arnau AG, Ferrer M, Jauregui I, Ballesteros C. Validation of the Spanish version of the urticaria activity score (Uas) and its use over one week (Uas7). Value Health. 2015;18(7):A426.
21. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med.2019;381(14):1321-1332.
22. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med.2013;368(10):924-935.
23. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol.1999;140(4):667-671.
24. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol.2006;154(2):294-298.
25. Ue AP, Souza PK, Rotta O, Wde JF, Lima AR, Sabbag DS. Quality of life assessment in patients with chronic urticaria. An Bras Dermatol. 2011;86(5):879-904.
26. Cavariani Silvares MR, Parise Fortes MR, Miot HA. Qualidade de vida em urticária crônica: inquérito em ambulatório público universitário, Botucatu (Brasil). Rev Assoc Med Bras. 2011;57(5):577-582.
27. Choi WS, Lim ES, Ban GY, et al. Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria.Korean J Intern Med. 2018;33(1):185-192.
28. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatology Venereol. 2017;31(6):1056-1063.
29. Oles-Krykowska A, Badura-Brzoza K, Brzoza Z. Does angioedema influence the quality of life in patients with chronic spontaneous urticaria? Ann Allergy Asthma Immunol. 2019;122(5):539-541.
30. Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2018;73(4):940-948.
31. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2011;66(3):428-433.
32. Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876-882.
33. Grattan CEH, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003;33(3):337-341.
34. Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8(1):318-325.
35. Jauregui I, Gimenez-Arnau A, Bartra J, et al. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study). Health Qual Life Outcomes.2019;17(1):1-9.